Immune Checkpoint Inhibitors Market Expected to Touch US$ 30,000 Mn by 2026

MK-1966 and Keytruda. Various niche players in the market are also exploring
immune checkpoint inhibitors’ potential in treating patients with cancer through
the development of next-generation immune checkpoint inhibitors therapy.
Browse Full Research Report:
https://www.persistencemarketresearch.com/market-research/immunecheckpoint-inhibitors-market.asp
North America and Europe to Lead Global Immune Checkpoint Inhibitors
Market in Terms of Revenues
In terms of revenues, North America and Europe will continue to lead the
global immune checkpoint inhibitors market, however the latter will register a
relatively faster expansion through 2026. In addition, Asia-Pacific excluding
Japan (APEJ) is projected to ride on the highest CAGR in the market through
2026, followed by Japan. Growth of the market in APEJ can be highly
attributed to rising number of research collaborations between international
players and companies in this region. However, the market in Japan will
account for comparatively larger revenues than that in APEJ by 2026-end.
Although PD-1 among drug class will continue to be the most lucrative, sales of
PD-L1 are projected to register the highest CAGR in the global immune
checkpoint inhibitors market through 2026. PD-L1 have been deemed
successful in treating Merkel cell carcinoma, non-small cell lung cancer, and
bladder cancer. In addition, a number of studies are being carried out for use of
PD-L1 inhibitors for various other types of cancer. CTLA-4 are anticipated to
remain the least lucrative drug class of immune checkpoint inhibitors
throughout the forecast period.
Request and Download Sample Report@
https://www.persistencemarketresearch.com/samples/20122
Key Research Findings from PMR’s Report on Immune Checkpoint
Inhibitors
Urothelial carcinoma and squamous cell carcinoma are projected to be the
fastest growing therapeutic applications of immune checkpoint inhibitors and
are collectively poised to account for over 40% revenue share of the market by
2026-end. Sales of immune checkpoint inhibitors for treating colorectal cancer
and blood cancers are also expected to witness a robust expansion through 2026.
In terms of revenues, hospital pharmacies will continue to be the largest
distribution channels for immune checkpoint inhibitors, owing to increasing